These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Coller BS; Lang D; Scudder LE Circulation; 1997 Feb; 95(4):860-7. PubMed ID: 9054743 [TBL] [Abstract][Full Text] [Related]
8. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
9. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173 [TBL] [Abstract][Full Text] [Related]
10. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997 [TBL] [Abstract][Full Text] [Related]
11. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction. Desch S; Siegemund A; Scholz U; Adam N; Eitel I; de Waha S; Fürnau G; Lurz P; Wetzel S; Schuler G; Thiele H Clin Res Cardiol; 2012 Feb; 101(2):117-24. PubMed ID: 22015616 [TBL] [Abstract][Full Text] [Related]
12. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Konstantopoulos K; Kamat SG; Schafer AI; Bañez EI; Jordan R; Kleiman NS; Hellums JD Circulation; 1995 Mar; 91(5):1427-31. PubMed ID: 7867183 [TBL] [Abstract][Full Text] [Related]
13. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Osende JI; Fuster V; Lev EI; Shimbo D; Rauch U; Marmur JD; Richard M; Varon D; Badimon JJ Circulation; 2001 Mar; 103(11):1488-91. PubMed ID: 11257073 [TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000 [TBL] [Abstract][Full Text] [Related]
15. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects. Abernethy DR; Pezzullo J; Mascelli MA; Frederick B; Kleiman NS; Freedman J Clin Pharmacol Ther; 2002 Mar; 71(3):186-95. PubMed ID: 11907493 [TBL] [Abstract][Full Text] [Related]
17. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861 [TBL] [Abstract][Full Text] [Related]
18. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G; Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353 [TBL] [Abstract][Full Text] [Related]
19. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173 [TBL] [Abstract][Full Text] [Related]
20. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty. Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]